Dexcom was issued with an FDA warning letter after issues with “manufacturing processes and quality management systems.” ...

Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last week citing issues at two of its manufacturing facilities. The warning ...

Shares of DexCom (DXCM) sank after the manufacturer of glucose monitoring devices said it had received a warning letter from the Food and Drug Administration (FDA) about conditions at two of its ...

Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the positions showed up on publicly available ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products ...

Investors with a lot of money to spend have taken a bullish stance on DexCom DXCM. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Analyst Price Forecast Suggests 14.60% Upside As of January 28, 2025, the average one-year price target for DexCom is $99.51/share. The forecasts range from a low of $75.75 to a high of $131.25.

DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is working on a written response. The diabetes devices ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company. It focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems.

Bengaluru: Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following inspections of its two key manufacturing facilities, sending its ...